Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Locoregional Approaches in Hepatocellular Carcinoma

February 9th 2018

KEYNOTE-224: Second-Line Pembrolizumab

February 9th 2018

Immunotherapy Approaches in Hepatocellular Carcinoma

February 9th 2018

CELESTIAL Trial: Second-Line Cabozantinib's Value in HCC

February 9th 2018

REFLECT Trial: Frontline Lenvatinib's Value in HCC

February 9th 2018

Hepatocellular Carcinoma: A Changing Treatment Landscape

February 9th 2018

Overman Highlights Latest Nivolumab Results in MSI-H/dMMR mCRC

February 8th 2018

Michael J. Overman, MD, discusses updated findings from the single-agent nivolumab CheckMate-142 cohort and combination data for nivolumab/ipilimumab from the pivotal trial.

Dr. Overman Discusses Immunotherapy and MSI Testing in CRC

February 8th 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy and microsatellite instability (MSI) testing in colorectal caner (CRC).

Alpelisib Active in PIK3CA-Altered Solid Tumors

February 8th 2018

Alpelisib (BYL719) induced a disease control rate of 58.2% and stable disease rate of 52.2% in patients with advanced solid tumors.

CRC: Deciding on Duration of Adjuvant Therapy

February 8th 2018

Antibody Selection and Tumor Sidedness in CRC

February 8th 2018

Implications of Recent Data from CheckMate-142 in CRC

February 8th 2018

Early-Onset Colorectal Cancer: What Do We Know?

February 8th 2018

Cabozantinib Active in Carcinoid Tumors and Pancreatic NETs

February 8th 2018

Jennifer A. Chan, MD, discusses the significance of the phase II results of cabozantinib in patients with carcinoid tumors and pancreatic NETs.

Dr. Bekaii-Saab Discusses the ReDOS Study in Metastatic CRC

February 6th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer.

Kulke Sheds Light on Emerging Agents for Neuroendocrine Tumors

February 6th 2018

Matthew Kulke, MD, discusses the evolving treatment paradigm for patients with neuroendocrine tumors.

Dr. Pishvaian on Molecular Alteration in Pancreatic Cancer

February 6th 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the background of a study investigating molecular alterations for patients with pancreatic cancer.

Dr. Abou-Alfa on Sequencing Agents in the Treatment of Patients With HCC

February 3rd 2018

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of cabozantinib (Cabometyx) in hepatocellular carcinoma (HCC) could affect the treatment landscape in liver cancer.

Dr. Singh Discusses the Future of Immunotherapy in GIST

February 1st 2018

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses the future of immunotherapy in gastrointestinal stromal tumors (GIST).

Dr. Jarnagin on Surgical Protocols for CRC That Have Spread Beyond the Liver

February 1st 2018

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the surgical barriers in treating patients with colorectal cancer that has metastasized outside of the liver.